Aga Khan University Hospital Launches Clinical Trial of KRAS Inhibitor GDC-6036 in Kenya
• A new clinical trial in Kenya is evaluating Roche's GDC-6036, a novel drug targeting the KRAS gene, in cancer patients.
• The trial aims to determine if GDC-6036 can effectively block the mutation of the KRAS gene into the KRAS G12C variant, which is implicated in various cancers.
• The study emphasizes the importance of conducting clinical trials in Africa to develop therapies that are better suited to the genetic specifications of African populations.
• The trial seeks to provide new treatment options for cancer patients and contribute to the advancement of precision oncology in the region.
© Copyright 2025. All Rights Reserved by MedPath